Ohio State to partner with Zangmeister Cancer Center to expand access to cancer care
The OSUCCC – James announces today it will form a new partnership with Zangmeister Cancer Center, a partner practice of American Oncology Network. This
Related Articles
FDA Grants Priority Review to Durvalumab in MIBC
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of patients with muscle-invasive bladder cancer in this curative-intent…
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma
This randomized clinical trial evaluates the combination of veliparib and temozolomide in treating glioblastoma.
Neoadjuvant Therapy NCCN Recommendations Take the Melanoma Field in a New Direction
Douglas B. Johnson, MD, MSCI, unpacks NCCN guideline updates in melanoma, detailing how neoadjuvant and TIL therapies have been notable advancements.
Tamoxifen Reduces Ipsilateral Breast Recurrence in Good-Risk Ductal CIS
Tamoxifen reduced the risk of invasive ipsilateral breast recurrence in patients with good-risk ductal carcinoma in situ.
CAR-T cell therapies for T cell malignancies: does cellular immunotherapy represent the best chance of cure?
Chimeric antigen receptor T cell (CAR-T) therapy has proven successful for B cell lymphomas and leukaemias. This success has inspired the development of CA
Frontiers | Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma
1 The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China 2 China-New Zealand Joint Laboratory on Biomedicine and Health, Key Laboratory of Immune Response and…
Cilta-Cel Improves MRD-Negativity Rates in Lenalidomide-Refractory Myeloma
Cilta-cel boosted MRD-negativity rates in lenalidomide-refractory multiple myeloma, according to updated results from CARTITUDE-4.
FDA Grants Priority Review to Durvalumab in MIBC
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of patients with muscle-invasive bladder cancer in this curative-intent…
Considering 3-Year Follow-Up Data of Cilta-Cel in Multiple Myeloma
Samer A. Al’Hadidi, MD, discusses the follow-up data for ciltacabtagene autoleucel in patients with multiple myeloma.
Hot Mulled Cider | Recipes | Cook For Your Life
Hot mulled cider is a real treat to sip, plus it is also a perfect seasonal non-alcoholic drink for holiday parties.
